Document is current
Any future updates will be listed below
-
Authors
Dvir-Szternfeld, Raz
Castellani, Giulia https://orcid.org/0000-0002-0611-5250
Arad, Michal
Cahalon, Liora
Colaiuta, Sarah Phoebeluc
Keren-Shaul, Hadas
Croese, Tommaso https://orcid.org/0000-0002-3805-3429
Burgaletto, Chiara https://orcid.org/0000-0002-5517-8223
Baruch, Kuti
Ulland, Tyler
Colonna, Marco https://orcid.org/0000-0001-5222-4987
Weiner, Assaf https://orcid.org/0000-0002-5389-9668
Amit, Ido https://orcid.org/0000-0003-2968-877X
Schwartz, Michal https://orcid.org/0000-0003-4015-7507
- License Information
-
More Information
Article History
Received: 22 November 2020
Accepted: 4 November 2021
First Online: 20 December 2021
Competing interests
: M.S. is an inventor of the intellectual property that forms the basis for development of PD-L1 immunotherapy for AD. K.B. is coinventor of the intellectual property that forms the basis for development of PD-L1 immunotherapy for AD. The remaining authors declare no competing interests.
